BC Week In Review | Mar 1, 2017
Clinical News

Ecopipam: Ph IIb PSY302 data

Data from 40 Tourette’s patients ages 7-17 in the double-blind, U.S. Phase IIb PSY302 trial showed that once-daily oral ecopipam met the primary endpoint, leading to a mean 5 point reduction in YGTSS-TTS from baseline...
BC Week In Review | Feb 8, 2016
Clinical News

Ecopipam: Phase IIb ongoing

Psyadon said an independent DSMB recommended continuation of the double-blind, crossover, U.S. Phase IIb PSY302 trial evaluating 50 and 100 mg ecopipam once daily based on an interim data review of 15 patients. Psyadon said...
BC Week In Review | Jun 9, 2014
Clinical News

Ecopipam: Phase IIb started

Psyadon began the double-blind, crossover, U.S. Phase IIb PSY302 trial to evaluate 50 and 100 mg ecopipam once daily in about 30 patients with Tourette's syndrome ages 7-17 years. Patients will receive either ecopipam or...
BC Week In Review | Mar 4, 2013
Clinical News

Ecopipam: Phase III started

Psyadon began the double-blind, placebo-controlled, crossover, international Phase III PSY102 trial to evaluate once-daily 50 and 100 mg ecopipam for 18 weeks in about 24 patients. The trial includes an open-label extension for up to...
BC Week In Review | Jul 30, 2012
Clinical News

Ecopipam: Interim Phase II data

Psyadon stopped the open-label, U.S. Phase II PSY301 trial after an interim analysis of 15 evaluable patients with Tourette's syndrome in the intent-to-treat (ITT) population showed that once-daily ecopipam met the primary endpoint of reducing...
BC Extra | Jul 25, 2012
Clinical News

Psyadon's ecopipam meets Phase II Tourette's endpoint

Psyadon Pharmaceuticals Inc. (Germantown, Md.) said an interim analysis showed ecopipam met the primary endpoint of reducing Yale Global Tic Severity Score from baseline to week eight in the Phase II PSY301 trial to treat...
BC Week In Review | May 23, 2011
Clinical News

Ecopipam: Phase IIa started

Psyadon began an open-label, U.S. Phase IIa to evaluate 50 and 100 mg once-daily ecopipam for 8 weeks in about 16 adult patients. Psyadon has exclusive, worldwide rights to ecopipam from Schering-Plough Corp. , now part...
BC Week In Review | Feb 15, 2010
Clinical News

Ecopipam: Phase Ib start

This month, Psyadon plans to begin an open-label, dose-escalation, U.S. Phase Ib trial in 6 patients. The trial will enroll two adults, two adolescents ages 11-17, and two children ages 7-11 to receive up to...
BC Week In Review | Nov 17, 2008
Company News

Psyadon, Schering-Plough deal

Schering-Plough granted Psyadon (formerly Ruxton Pharmaceuticals Inc.) an exclusive, worldwide license to develop and commercialize ecopipam (formerly SCH 39166 ) for all indications. Ecopipam was in Phase III testing to treat obesity, Phase IIa testing to...
Items per page:
1 - 9 of 9